Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

ts.

Discovery's lead product candidate, Surfaxin(r), is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. Surfaxin is also being developed for other neonatal and pediatric indications. Aerosurf(tm), Discovery's aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect Discovery's actual results and could cause results to differ from those contained in these forward-looking statements are the risk that Discovery may not profitably develop and market its products, the risk that financial market conditions may change, the risk that Discovery will not be able to raise additional capital or enter into additional collaboration agreements, the risk that Discovery will not be able to attract or retain qualified personnel or timely provide for a successful sales and marketing organization, risks relating to the progress of Discovery's research and development,, risks in the FDA or other regulatory agency review process generally, including that such regulatory authority will not approve the marketing and sale of a drug product even after acceptance of an application or that approval by such regulatory agency may be withheld, delayed and/or limited by indications or other label limita
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:5/27/2015)... BUENA, N.J. , May 27, 2015  IGI ... Jersey -based specialty generic pharmaceutical company, today updated ... Second Quarter and Full Year 2015 Updated ... three months ended June 30, 2015 are still expected ... sequential improvement quarter over quarter in total revenue for ...
(Date:5/27/2015)... ZIONA, Israel , May 27, 2015 /PRNewswire/ ... Capital has led an investment round of $10 million in ... participation by the company,s chairman and CEO Mr. Ehud ... company,s clinical development plans; the funding is sufficient to advance ... once every four weeks injection, currently at Phase II, up ...
(Date:5/27/2015)... , 27. Mai 2015 Experten ... GERD) diskutierten im Rahmen einer Spezialpräsentation auf ... Erfahrungen mit der Stretta-Therapie für ... Patientengruppen. Infografik - ... , MD, von der Case Western Reserve ...
Breaking Medicine Technology:IGI Laboratories Updates Business Outlook 2IGI Laboratories Updates Business Outlook 3Mapi Pharma Closes $10 Million Investment Led by Shavit Capital 2DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen 2DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen 3DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen 4
... Sigma-Aldrich (Nasdaq: SIAL ) announced today that it ... leader in bench top flow chemistry instruments, the terms ... of approximately 400 CatCart® catalyst products for flow chemistry ... and CatCart catalyst cartridges provide organic chemists in academic ...
... Accumetrics, Inc., developer and marketer of the VerifyNow® ... measuring an individual,s response to multiple antiplatelet agents, announced ... that will raise $16.5 million in new capital. ... into 2011, came from the company,s existing investors, including ...
Cached Medicine Technology:Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market 2Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market 3Accumetrics Announces $16.5M in New Capital Financing 2Accumetrics Announces $16.5M in New Capital Financing 3
(Date:5/27/2015)... (PRWEB) May 27, 2015 SAN ... in Gulfport Mississippi, is the first healthcare provider ... approach to chronic care management (CCM). In partnership ... Memorial is introducing RevUp, a new program that ... requirements and increase monthly reimbursements. This new, user-friendly ...
(Date:5/27/2015)... HOUSTON, Tx (PRWEB) May 27, 2015 ... combined germline pharmacogenomic and somatic genomic analysis in personalized ... was published by the American Society of Clinical Oncology ... – June 2 in Chicago. , The molecular and ... The Cancer Genome Atlas (TCGA) database. The study reports ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 On June ... advertising agency, will partner with LifeSource to host Donate ... will take place in a LifeSource donor coach outside ... to 4:00 p.m. , Demand for whole blood units ... Illinois, during the summer months. LifeSource requires approximately 1,000 ...
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 ... the current state of the Omega-3 industry. The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ... Gc Rieber Oils, Camanchaca Fishing Company, Seadragon Marine ...
(Date:5/27/2015)... May 27, 2015 SonarMD, ... SonarMD Platform, a first-of-its kind, cloud-based algorithmic ... patients with chronic gastrointestinal disease. , Developed ... the application allows physicians to monitor their ... ongoing use of electronic health assessment surveys. ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... A new vaccine called the TAT vaccine has been developed ... to date. And more importantly it has had a 71% ... ready for human testing and this may be the brightest ... Head of the Department of Virology at Italy’s National Health ...
... Allergy and asthma patients can now breathe easy. Literally. A ... be effective in improving the quality of life and has ... findings of this study are reported in the latest issue ... M. Walker, PhD, of the Imperial College School of Medicine ...
... been used to test the importance of sleep for ... of side effects, such as fatigue and reduced alertness. ... circumventing these complications by allowing recovery sleep by Harvard ... the first day showed no improvement in task performance ...
... so aggressive and almost impossible to handle at times? Then read ... the children of today are growing up. Even the West is ... India. With the TV boom and the IT revolution, the kids ... parents complain that their kids are actually going over the edge, ...
... at the just concluded Indian science congress in New Delhi ... combat anemia with iron fortification of crops. Almost 50% of ... anemic in India. While iron supplementation is expensive, fortification of ... anemia in people is fairly cheaper, scientists say. ,This ...
... to increased risk of heart problems to their children ... several aspects of cardiovascular risks in adult life, but ... mothers starved during the first 13 weeks of pregnancy ... Starvation during mid or late pregnancy don’t have a ...
Cached Medicine News:
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Elisa Plate Reader...
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Medicine Products: